Cite
HARVARD Citation
Sweet, K. et al. (2019). Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Annals of the rheumatic diseases. 78 (10), pp. 1439-. [Online].